Global Irritable Bowel Syndrome (IBS) Market 2024 by Company, Regions, Type and Application, Forecast to 2030

Global Irritable Bowel Syndrome (IBS) Market 2024 by Company, Regions, Type and Application, Forecast to 2030

Irritable bowel syndrome (IBS) is defined as recurrent abdominal pain or discomfort that occurs in association with altered bowel habits over a period of at least 3 months. The disorder is classified into three main subtypes, according to the predominant bowel habits presented: constipation-predominant IBS (IBS-C), diarrhea-predominant IBS (IBS-D), and mixed-presentation IBS (IBS-M). IBS is among the most common gastrointestinal disorders, with an estimated pooled international IBS prevalence rate of about 11.2%.

According to our (Global Info Research) latest study, the global Irritable Bowel Syndrome (IBS) market size was valued at US$ 5668 million in 2023 and is forecast to a readjusted size of USD 14610 million by 2030 with a CAGR of 14.6% during review period.

North America is the largest region of Irritable Bowel Syndrome (IBS), with a market share about 75%. Allergan, Valeant Pharmaceuticals, Takeda, Sucampo Pharmaceuticals and McNeil Consumer Healthcare are the top 5 manufacturers of industry, and they had about 80% combined market share.

This report is a detailed and comprehensive analysis for global Irritable Bowel Syndrome (IBS) market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2024, are provided.

Key Features:

Global Irritable Bowel Syndrome (IBS) market size and forecasts, in consumption value ($ Million), 2019-2030

Global Irritable Bowel Syndrome (IBS) market size and forecasts by region and country, in consumption value ($ Million), 2019-2030

Global Irritable Bowel Syndrome (IBS) market size and forecasts, by Type and by Application, in consumption value ($ Million), 2019-2030

Global Irritable Bowel Syndrome (IBS) market shares of main players, in revenue ($ Million), 2019-2024

The Primary Objectives in This Report Are:

To determine the size of the total market opportunity of global and key countries

To assess the growth potential for Irritable Bowel Syndrome (IBS)

To forecast future growth in each product and end-use market

To assess competitive factors affecting the marketplace

This report profiles key players in the global Irritable Bowel Syndrome (IBS) market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Bausch Health, Allergan, Takeda, Sucampo Pharmaceuticals (Mallinckrodt), Sebela Pharmaceuticals Inc, Astellas Pharmaceuticals, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Market segmentation

Irritable Bowel Syndrome (IBS) market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segmentation

Irritable Bowel Syndrome (IBS) market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type
IBS-D Drug
IBS-C Drug
Others

Market segment by Application
Women
Men

Market segment by players, this report covers
Bausch Health
Allergan
Takeda
Sucampo Pharmaceuticals (Mallinckrodt)
Sebela Pharmaceuticals Inc
Astellas Pharmaceuticals

Market segment by regions, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia, Italy and Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)

South America (Brazil, Rest of South America)

Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 13 chapters:

Chapter 1, to describe Irritable Bowel Syndrome (IBS) product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top players of Irritable Bowel Syndrome (IBS), with revenue, gross margin, and global market share of Irritable Bowel Syndrome (IBS) from 2019 to 2024.

Chapter 3, the Irritable Bowel Syndrome (IBS) competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.

Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2019 to 2030.

Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2019 to 2024.and Irritable Bowel Syndrome (IBS) market forecast, by regions, by Type and by Application, with consumption value, from 2024 to 2030.

Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.

Chapter 12, the key raw materials and key suppliers, and industry chain of Irritable Bowel Syndrome (IBS).

Chapter 13, to describe Irritable Bowel Syndrome (IBS) research findings and conclusion.